Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
ID: HT9402-24-Q-9403Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYAURORA, CO, 80011, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/6d8c69e2153f4b9db6f11f1176f524d5/view
Timeline
    Description

    The Department of Defense (DoD) is issuing a Request for Quotation (RFQ) for the establishment of Blanket Purchase Agreements (BPA) and Additional Discount Program (ADP) agreements related to pharmaceutical agents under the Defense Health Agency's Uniform Formulary (UF). This procurement aims to secure pricing agreements for various newly approved drugs, including those in the classes of Parkinson's agents, gastrointestinal agents, respiratory agents, hematological agents, targeted immunomodulatory biologics, anticonvulsants, and oncological agents, which will be reviewed during the Pharmacy and Therapeutics (P&T) Committee meeting scheduled for November 6-7, 2024. The initiative is crucial for maintaining an effective pharmacy benefits program for the Military Health System (MHS), ensuring that military personnel have access to high-value medications while adhering to cost-effectiveness criteria. Interested manufacturers must submit their quotes by September 19, 2024, and can direct inquiries to primary contact Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil or secondary contact Tracy Banks at tracy.e.banks2.civ@health.mil.

    Point(s) of Contact
    Stephanie Erpelding
    stephanie.j.erpelding.civ@health.mil
    Tracy Banks
    tracy.e.banks2.civ@health.mil
    Files
    Title
    Posted
    DoD Formulary Placement of FDA Newly Approved Drugs.pdf
    The document outlines the process for formulary placement of newly approved innovator drugs within the TRICARE Pharmacy Benefits Program as set by the Department of Defense (DoD). Effective from August 26, 2015, the Pharmacy and Therapeutics (P&T) Committee has a 120-day window to recommend tier placements for FDA-approved medications, categorizing them into four tier levels based on clinical and cost-effectiveness evaluations. Newly approved drugs will initially hold a pending status, pending pricing information and evaluations scheduled quarterly. The final approval for formulary placements rests with the Defense Health Agency (DHA) Director. To foster cost-effectiveness, the government will solicit pricing submissions from manufacturers through Uniform Formulary Blanket Purchase Agreements (UF BPA). While Tier 3 drugs require prescriber justification to be available at military treatment facilities (MTFs), they remain accessible through TRICARE’s mail-order and retail options at higher copay levels unless exceptions apply. Notably, the document affirms that due to the significant volume of newly approved drugs, clinical presentations from manufacturers will not be considered during evaluations. This procedure aims to uphold efficient pharmaceutical management within military healthcare systems.
    NDC Price List Crexont - Parkinsons Agents - NA.xlsx
    The document outlines a Request for Quotes (RFQ) related to newly approved Parkinson's agents to be discussed at the Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee meeting scheduled for November 6-7, 2024. Quotes from manufacturers are due by September 19, 2024. The document details requirements for submitting quotes, including National Drug Code (NDC) numbers, drug names, strengths, dosage forms, package sizes, and conditions for both uniform and non-formulary agents. Additionally, it specifies the potential application of prior authorization and the opportunity for drugs to be prioritized for favorable reimbursement under the TRICARE program as Tier 1 costs, equivalent to generic agents. The document emphasizes the importance of adherence to submission guidelines, including required signature pages, and highlights potential penalties for non-compliance. It aims to encourage the selection of high-value pharmaceutical products while monitoring submissions for fairness and transparency. Overall, the RFQ stresses cooperative engagement between the Department and drug manufacturers to facilitate the procurement of effective medication for military personnel suffering from Parkinson's Disease.
    NDC Price List Livdelzi - Gastrointestinal-2 Agents - NA.xlsx
    The document outlines a Blanket Purchase Agreement and Additional Discount Program related to newly approved drugs in the DOD Uniform Formulary Class of Gastrointestinal-2 agents. A P&T Committee Meeting is scheduled for November 6-7, 2024, with quotes due by September 19, 2024. Several new drugs are listed, including their National Drug Code (NDC), drug name, strength, and packaging details. The summary also notes the potential for Prior Authorization (PA) requirements and that the committee may consider preferential status for certain non-generic agents and exclude others from the TRICARE pharmacy benefit. Manufacturers are advised to submit fully executed signature pages with their quotes and confirm submission intents when applicable. Overall, the document emphasizes compliance with cost-sharing policies and encourages the use of high-value products to optimize pharmaceutical procurement for military healthcare needs.
    NDC Price List Neffy - Respiratory Agents Misc.- NA.xlsx
    The document outlines a call for quotes in relation to the Department of Defense (DOD) Uniform Formulary for newly approved respiratory agents, set for discussion during the P&T Committee Meeting scheduled for November 6-7, 2024. Quotes for these agents are required by September 19, 2024, covering various drugs categorized under the class "Respiratory Agents Miscellaneous". Each entry includes National Drug Code (NDC) numbers, drug names, strengths, dosage forms, and pricing information. The Uniform Formulary is subject to review and may involve considerations for prior authorization and reimbursement. It also indicates potential steps to encourage the use of high-value pharmaceutical products and possibly recommend excluding low-value agents from the TRICARE pharmacy benefit. Finally, manufacturers are reminded to provide necessary documentation and signatures when submitting quotes. This call for quotes highlights the DOD's commitment to improving the pharmaceutical offerings available to its beneficiaries while ensuring cost-effectiveness and adherence to regulatory guidelines.
    NDC Price List Nemluvio - TIBS - Misc. Interleukins.xlsx
    The Department of Defense (DoD) has organized a Pharmacy and Therapeutics (P&T) Committee Meeting scheduled for November 6-7, 2024, focusing on Targeted Immunomodulatory Biologics, specifically under the subclass of Miscellaneous Interleukins. Quotes for newly approved drugs are required by September 19, 2024, as part of a Blanket Purchase Agreement. The document outlines assessment conditions and pricing details for various National Drug Code (NDC) numbers related to these drugs. Each NDC entry specifies information such as strength, dosage form, and package size alongside a requirement for manufacturers to submit executed signature pages with their quote information. Additionally, there is mention of a step therapy protocol for new patients, requiring adequate trials of preferred agents before accessing non-preferred drugs. The document emphasizes the importance of adhering to TRICARE regulations and provides guidance on the calculation of federally mandated refund processes across different drug tiers. Overall, the document serves as a call for proposals from manufacturers while providing critical information on the conditions and requirements necessary for participation in the upcoming P&T Committee Meeting.
    NDC Price List Vafseo - Hematological - NA.xlsx
    The document outlines the Department of Defense's (DOD) Uniform Formulary Class for Hematological Agents, detailing the preparations for an upcoming Pharmacy and Therapeutics (P&T) Committee meeting scheduled for November 6-7, 2024. It includes important dates, such as the deadline for quotes, which is September 19, 2024. The file lists multiple newly approved drugs categorized under hematological agents but indicates that no quotes have yet been received for the specified items. Manufacturers are reminded to submit completed signature pages along with their quotes, and several stipulations about pricing and refund calculations highlight the program's regulatory framework. The document emphasizes the use of expensive high-value drugs over low-value alternatives through special reimbursement methods. Additionally, agents may be designated for step therapy, impacting coverage under the TRICARE pharmacy benefit program. This information is crucial for manufacturers looking to supply drugs to the military healthcare system, ensuring compliance with procurement processes and reimbursement strategies. The focus on timely submissions and adherence to specific regulatory guidelines highlights the document's role in streamlining drug procurement within the DOD.
    NDC Price List Vigafyde - Anticonvulsants-Antimania - NA.xlsx
    The document pertains to the Department of Defense (DOD) Uniform Formulary for Anticonvulsants and Antimanic Agents, with a focus on drug procurement through a Blanket Purchase Agreement. The Pharmacy and Therapeutics (P&T) Committee meeting scheduled for November 6-7, 2024, will serve as a platform to review newly approved drugs, with quotes due by September 19, 2024. Each drug's inclusion is categorized, with specific notes regarding pricing, including the Non-Formulary status and conditions for prior authorization. The document outlines procedures for manufacturers to submit drug quotes, including details on package sizes and pricing structures, emphasizing that identical pricing applies to various packaging options. Notably, the document mentions special reimbursement methodologies to promote high-value medications and guide exclusions from the TRICARE pharmacy program. Instructional notes illustrate the importance of submitting executed signature pages and address drug pricing standards based on the Wholesale Acquisition Cost (WAC). It underscores that the upcoming review process aims to optimize medication value and accessibility for military treatment facilities. The document serves both as a formal RFP for pharmaceutical providers and a guiding framework for drug formulary management within TRICARE, reflecting the government’s commitment to effective and cost-efficient healthcare solutions for service members.
    NDC Price List Voranigo - Oncological Agents - NA.xlsx
    The Department of Defense (DOD) is preparing for a Pharmacy and Therapeutics (P&T) Committee Meeting scheduled for November 6-7, 2024, focusing on the inclusion of newly approved oncological agents in the DOD Uniform Formulary. Quotes for these drugs are expected by September 19, 2024. Each drug will be evaluated for its pricing and formulary status, with consideration for Prior Authorization and reimbursement methodologies aimed at promoting high-value products. The P&T Committee may also recommend preferential treatment for specific non-generic agents, potentially allowing certain products to be treated as generic for cost-sharing purposes. Furthermore, the document highlights the importance of manufacturers submitting complete quote packages, including signature pages, to ensure proper processing. The pricing structure includes a federal ceiling price and additional discounts, reflecting an objective to optimize the pharmaceutical benefit program within the TRICARE framework. This initiative emphasizes the DOD's commitment to maintaining drug efficacy and cost-effectiveness in military healthcare.
    Price Appendix FAQ NAD.pdf
    The Price Appendix FAQ outlines the procedures and requirements for submitting quotes for National Drug Codes (NDCs) in response to government RFPs. It emphasizes the importance of reviewing the Formulary Notes to comprehend the decision-making process of the Pharmacy and Therapeutics (P&T) committee regarding formulary status. Three main sections detail the requirements for BPA, ADP (non-FAMP Discount), and ADP (WAC Discount). Each section instructs users to fill in specific yellow cells on attached spreadsheets while most fields remain locked for editing to ensure consistency. The documents feature tables for a maximum of 10 NDCs, stating those wishing to submit more must contact Points of Contact (POCs) for additional tables. Key calculations for prices and discounts are included, ensuring convenience for users, and highlighting that zero percentage offers will signal non-participation in certain categories. These structured guidelines aim to facilitate compliance and streamline the quotation process for pharmaceutical products in federal procurement contexts, ensuring clarity and efficiency in submissions to the P&T committee.
    RFQ HT9402-24-Q-9403 NAD.pdf
    The Department of Defense (DOD) is issuing a Request for Quotation (RFQ) regarding the establishment of pricing agreements for pharmaceutical agents under the Defense Health Agency (DHA) Uniform Formulary (UF). This RFQ invites manufacturers to provide price quotes for pharmaceuticals intended for the Military Health System (MHS) based on clinical and cost-effectiveness criteria established by the DOD Pharmacy and Therapeutics Committee. The document details the submission process for quotes, including timelines and specific requirements for quotes involving Blanket Purchase Agreements (UF BPA) and Additional Discount Programs (UF ADP). Key steps include downloading datasets, completing required forms, and attending a pre-quotation teleconference to clarify procedures. Quotes must adhere to structured pricing formats for military treatment facilities and retail pharmacy networks. The DOD reserves the right to reject specific formulations based on P&T recommendations and will evaluate drug agents based on clinical effectiveness, cost share classifications, and potential inclusion on formularies. Appendices provide additional instructions for manufacturers regarding submission checklists, expected pricing formats, and definitions relevant to the RFQ. The overarching goal is to secure favorable pricing and availability of essential medications for military personnel and their families, highlighting the DOD's commitment to efficient healthcare management.
    Similar Opportunities
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense (DoD) is soliciting quotations for pharmaceutical agents under the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at enhancing the Military Health System's pharmacy benefits. This procurement process is governed by 10 U.S.C. § 1074g and involves the evaluation of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on specific drug classes such as Oral CGRP migraine agents and Interleukin 17 and 23 targeted immunomodulatory biologics. Interested manufacturers must submit their quotes by September 19, 2024, following a pre-quotation teleconference scheduled for July 24, 2024, and can direct inquiries to primary contacts Stephanie Erpelding and Tracy Banks via their provided emails.
    Repaglinide
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.
    Famotidine
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Pantoprazole DR Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Telmisartan Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Telmisartan Tablets. Telmisartan Tablets are pharmaceutical preparations used to treat high blood pressure and reduce the risk of heart attack, stroke, and kidney problems in certain patients. The tablets will be available in 20MG, 40MG, and 80MG strengths, packaged in 30 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide Telmisartan Tablets to Department of Defense, Bureau of Prisons, Indian Health Service, and Department of Veterans Affairs customers through the DLA and VA prime vendor programs. Interested parties can contact Courtney Hunter-Stangler at (215) 737-6845 or Courtney.Hunter-Stangler@dla.mil for any questions/comments. The solicitation is projected to be issued in August of 2024.
    Rabeprazole Sodium Delayed Release Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Doxycycline Hyclate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    Dimethyl Fumarate DR Presolicitation
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Dimethyl Fumarate DR capsules. The contract will establish a national supply source for the purchase of these capsules by Department of Defense customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on DLA Bid Board System and Beta Sam.Gov. Interested parties should contact Kevin Rafferty for any questions/comments. The projected solicitation date is February 2021.
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used for treating high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties can contact Catherine Gilbert for more information. The solicitation is projected to be issued in December 2019.
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.